as of 01-07-2026 1:04pm EST
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
| Founded: | 2007 | Country: | Australia |
| Employees: | N/A | City: | CAMBERWELL, VICTORIA |
| Market Cap: | 20.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 64.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.50 - $145.46 | Next Earning Date: | 02-15-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
See how PPCB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PPCB Propanc Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.